AN2 Therapeutics, Inc. (ANTX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ANTX
- Company AN2 Therapeutics, Inc.
- Price $1.3
- Changes Percentage 22.64
- Change 0.24
- Day Low $1.07
- Day High $1.33
- Year High $22.22
- Year Low $0.87
- Market Cap $38,795,159
- Price Avg 50 EMA (D) $1.06
- Price Avg 200 EMA (D) $2.53
- Exchange NASDAQ
- Volume 5,495,081
- Average Volume 346,980
- Open $1.07
- Previous Close $1.06
- EPS -1.99
- PE -0.65
- Earnings Announcement 2025-03-27 04:00:00
- Shares Outstanding $29,842,430
Company brief: AN2 THERAPEUTICS, INC. (ANTX )
- Healthcare
- Biotechnology
- Mr. Eric E. Easom
- https://www.an2therapeutics.com
- US
- N/A
- 03-25-2022
- US0373261058
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.